Please assess the completion status of the following clinical trial:

Trial Title: Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, postmenopausal women (no vaginal bleeding for at least 2 years prior to screening) with osteoporosis~* Bone mineral density (BMD) T-score of at least -2.5 at femoral neck (FN), total hip (TH), or lumbar spine (LS) (Lumbar vertebrae L1-L4, with at least 2 evaluable vertebrae), with or without atraumatic fracture after menopause, OR~* BMD T-score of at least -1.5 at FN, TH, or LS (L1-L4, with at least 2 evaluable vertebrae), and 1 or more atraumatic fractures after menopause (vertebral or nonvertebral). Nonvertebral fracture sites allowed are wrist, hip, pelvis, rib, humerus, clavicle, leg (femur, tibia, and fibula, excluding ankle)~* Laboratory values for serum calcium, parathyroid hormone (PTH), and alkaline phosphatase must be within the normal reference range~Exclusion Criteria:~* Has an increased risk of osteosarcoma (bone tumor); this includes Paget's disease of bone, a previous bone tumor, or radiation involving the skeleton~* Has an allergy or intolerance to teriparatide or denosumab and/or is a poor candidate for teriparatide or denosumab treatment (investigator should refer to local product prescribing information)~* Has a history of exposure to DEM or TET therapy in the 12 months prior to screening or a known allergy to DEM or TET~* Has a condition that could put the participant at additional risk of an adverse event (AE) due to the bone biopsy procedure (for example, bleeding disorder)~* Has undergone 2 previous iliac crest bone biopsies (1 in each iliac crest)~* Has a 25-hydroxyvitamin D concentration of \<10 nanograms per milliliter (ng/mL)~* Has currently active or suspected (within 1 year prior to enrollment) diseases that affect bone metabolism, other than osteoporosis (such as renal osteodystrophy, hyperthyroidism, osteomalacia, or hyperparathyroidism)~* Has a history of certain cancers within 5 years prior to trial entry~* Current or recent (within 1 year prior to enrollment) celiac disease, inflammatory bowel disease, gastric bypass, or other malabsorption syndrome~* Has significantly impaired hepatic or renal function~* Has had treatment with systemic glucocorticoids in doses ≥5 mg/day prednisone/day or equivalent in the 6 calendar months prior to screening~* Has taken any intravenous osteoporosis medication~* Has had prior treatment with other bisphosphonates and not been off of them for a specific period of time before trial entry~* Has participated in any other clinical trial studying teriparatide, PTH, PTH analog, or denosumab, or prior or current treatment with teriparatide, PTH, PTH analog, or denosumab

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): 20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally.
- Denosumab (Type: ACTIVE_COMPARATOR): 60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete